

# Christopher G Parsons

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3890862/publications.pdf>

Version: 2024-02-01

75  
papers

4,945  
citations

134610

34  
h-index

100535

70  
g-index

76  
all docs

76  
docs citations

76  
times ranked

5832  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhalational Anesthetics Do Not Deteriorate Amyloid- $\beta$ -Derived Pathophysiology in Alzheimer's Disease: Investigations on the Molecular, Neuronal, and Behavioral Level. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1193-1218.	1.2	1
2	The $A\beta$ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of $A\beta^{1-42}$ on LTP even following serial dilution to a 500:1 stoichiometric excess of $A\beta^{1-42}$ , suggesting a beneficial prion-like seeding mechanism. <i>Neuropharmacology</i> , 2020, 179, 108267.	2.0	5
3	The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity. <i>Neuropharmacology</i> , 2019, 151, 21-32.	2.0	7
4	CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity. <i>Neuropharmacology</i> , 2019, 147, 4-10.	2.0	17
5	The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta ( $A\beta$ ) species on long-term potentiation (LTP). <i>Neuropharmacology</i> , 2018, 140, 184-192.	2.0	22
6	Involvement of GluN2B subunit containing N-methyl-d-aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta ( $A\beta$ ) in murine models of Alzheimer's disease (AD). <i>Neuropharmacology</i> , 2017, 123, 100-115.	2.0	29
7	Preclinical to phase II amyloid beta ( $A\beta$ ) peptide modulators under investigation for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 579-592.	1.9	23
8	MRZ-99030 - A novel modulator of $A\beta$ aggregation: II - Reversal of $A\beta$ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice. <i>Neuropharmacology</i> , 2015, 92, 170-182.	2.0	23
9	MRZ-99030 - A novel modulator of $A\beta$ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). <i>Neuropharmacology</i> , 2015, 92, 158-169.	2.0	27
10	Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships. <i>Journal of Neural Transmission</i> , 2015, 122, 1221-1238.	1.4	3
11	Brain concentrations of mGluR5 negative allosteric modulator MTEP in relation to receptor occupancy - Comparison to MPEP. <i>Pharmacological Reports</i> , 2015, 67, 624-630.	1.5	9
12	Patch Clamp Combined with Voltage/Concentration Clamp to Determine the Kinetics and Voltage Dependency of N-Methyl-d-aspartate (NMDA) Receptor Open Channel Blockers. <i>Methods in Molecular Biology</i> , 2014, 1183, 43-63.	0.4	1
13	Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer's Disease. <i>Neurotoxicity Research</i> , 2013, 24, 358-369.	1.3	246
14	Preparation and testing of homocubyl amines as therapeutic NMDA receptor antagonists. <i>Medicinal Chemistry Research</i> , 2013, 22, 360-366.	1.1	25
15	Lipid raft integrity affects GABAA receptor, but not NMDA receptor modulation by psychopharmacological compounds. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1361-1371.	1.0	29
16	GluN2A and GluN2B NMDA Receptor Subunits Differentially Modulate Striatal Output Pathways and Contribute to Levodopa-Induced Abnormal Involuntary Movements in Dyskinetic Rats. <i>ACS Chemical Neuroscience</i> , 2013, 4, 808-816.	1.7	13
17	Assessment of the effects of NS11394 and L-838417, $\alpha$ 2/3 subunit-selective GABAA receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function. <i>Behavioural Pharmacology</i> , 2012, 23, 790-801.	0.8	17
18	Alzheimer's disease, $A\beta$ , amyloid, glutamate, NMDA receptors and memantine - searching for the connections. <i>British Journal of Pharmacology</i> , 2012, 167, 324-352.	2.7	396

#	ARTICLE	IF	CITATIONS
19	Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1351-1365.	1.4	39
20	Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of $\beta$ -amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. <i>Neuropharmacology</i> , 2011, 60, 982-990.	2.0	141
21	Synthesis of a series of $\beta$ -amino alcohols comprising an N-methyl isoindoline moiety and their evaluation as NMDA receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5795-5799.	1.0	16
22	Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L-DOPA-induced dyskinesia. <i>Journal of Neural Transmission</i> , 2011, 118, 1703-1716.	1.4	25
23	In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons. <i>Journal of Neural Transmission</i> , 2010, 117, 1189-1194.	1.4	9
24	Memantine Improves Cognition and Reduces Alzheimer's-Like Neuropathology in Transgenic Mice. <i>American Journal of Pathology</i> , 2010, 176, 870-880.	1.9	188
25	Synergism of virtual screening and medicinal chemistry: Identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 5708-5715.	1.4	25
26	Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-d-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. <i>Neuropharmacology</i> , 2009, 56, 866-875.	2.0	63
27	Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from <i>Xenopus</i> oocytes. <i>Journal of Neural Transmission</i> , 2008, 115, 1367-1373.	1.4	6
28	Memantine does not show intracellular block of the NMDA receptor channel. <i>European Journal of Pharmacology</i> , 2008, 587, 99-103.	1.7	16
29	Positive and Negative Modulation of Group I Metabotropic Glutamate Receptors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 634-647.	2.9	49
30	Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-d-aspartate receptors by memantine. <i>Neuropharmacology</i> , 2007, 53, 415-420.	2.0	22
31	Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. <i>Neuropharmacology</i> , 2007, 53, 699-723.	2.0	593
32	Memantine as an Example of a Fast, Voltage-Dependent, Open Channel N-Methyl-d-Aspartate Receptor Blocker. <i>Methods in Molecular Biology</i> , 2007, 403, 15-36.	0.4	36
33	Searching for Drug Scaffolds with 3D Pharmacophores and Neural Network Ensembles. <i>Angewandte Chemie - International Edition</i> , 2007, 46, 5336-5339.	7.2	21
34	Virtual Screening for Selective Allosteric mGluR1 Antagonists and Structure-Activity Relationship Investigations for Coumarine Derivatives. <i>ChemMedChem</i> , 2007, 2, 1763-1773.	1.6	34
35	Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. <i>European Journal of Pharmacology</i> , 2007, 554, 18-29.	1.7	41
36	Inhibition of the $\alpha$ 10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-d-aspartate receptors. <i>European Journal of Pharmacology</i> , 2007, 566, 11-19.	1.7	31

#	ARTICLE	IF	CITATIONS
37	mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy. <i>Neuropharmacology</i> , 2006, 50, 1006-1015.	2.0	27
38	The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. <i>Neuropharmacology</i> , 2006, 51, 12-17.	2.0	43
39	Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. <i>Behavioural Pharmacology</i> , 2006, 17, 411-424.	0.8	118
40	Predicting Compound Selectivity by Self-Organizing Maps: Cross-Activities of Metabotropic Glutamate Receptor Antagonists. <i>ChemMedChem</i> , 2006, 1, 1066-1068.	1.6	54
41	3-Nitropropionic acid toxicity in hippocampus: Protection through N-methyl-D-aspartate receptor antagonism. <i>Hippocampus</i> , 2006, 16, 834-842.	0.9	33
42	New Allosteric Modulators of Metabotropic Glutamate Receptor 5 (mGluR5) Found by Ligand-Based Virtual Screening. <i>ChemBioChem</i> , 2005, 6, 620-625.	1.3	26
43	Peripherally acting NMDA receptor/glycine site receptor antagonists inhibit morphine tolerance. <i>Neuropharmacology</i> , 2005, 48, 360-371.	2.0	22
44	N-Methyl-d-Aspartate Receptors Mediate Endogenous Opioid Release in Enteric Neurons After Abdominal Surgery. <i>Gastroenterology</i> , 2005, 128, 2009-2019.	0.6	28
45	Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. <i>Neuropharmacology</i> , 2004, 47, 175-175.	2.0	0
46	Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. <i>Neuropharmacology</i> , 2004, 47, 175-183.	2.0	35
47	Chronic memantine does not block 3-nitropropionic acid-delayed ischaemic tolerance in rat hippocampal slices <i>in vivo</i> . <i>Neurotoxicity Research</i> , 2003, 5, 617-22.	1.3	5
48	Are neuronal nicotinic receptors a target for antiepileptic drug development? Studies in different seizure models in mice and rats. <i>European Journal of Pharmacology</i> , 2003, 466, 99-111.	1.7	36
49	The NMDA receptor antagonist memantine as a symptomatic and neuroprotective treatment for Alzheimer's disease: preclinical evidence. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, S23-S32.	1.3	327
50	Expression of Polyglutamine-expanded Huntingtin Induces Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors. <i>Journal of Biological Chemistry</i> , 2003, 278, 33364-33369.	1.6	79
51	Neuroprotective potential of ionotropic glutamate receptor antagonists. <i>Neurotoxicity Research</i> , 2002, 4, 119-126.	1.3	42
52	Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats. <i>Pain</i> , 2001, 91, 201-207.	2.0	19
53	NMDA receptors as targets for drug action in neuropathic pain. <i>European Journal of Pharmacology</i> , 2001, 429, 71-78.	1.7	210
54	Neuroprotective and symptomatic action of memantine relevant for Alzheimer's disease: a unified glutamatergic hypothesis on the mechanism of action. <i>Neurotoxicity Research</i> , 2000, 2, 85-97.	1.3	211

#	ARTICLE	IF	CITATIONS
55	Differential effects of NMDA receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. <i>Neuropharmacology</i> , 2000, 39, 631-642.	2.0	31
56	Expression of early hippocampal CA1 LTP does not lead to changes in AMPA-EPSC kinetics or sensitivity to cyclothiazide. <i>Pflügers Archiv European Journal of Physiology</i> , 1999, 437, 191-196.	1.3	14
57	Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. <i>Neuropharmacology</i> , 1999, 38, 85-108.	2.0	130
58	Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg <sup>2+</sup> in hippocampal slices. <i>Neuropharmacology</i> , 1999, 38, 1253-1259.	2.0	102
59	Electrophysiological Study, Biodistribution in Mice, and Preliminary PET Evaluation in a Rhesus Monkey of 1-Amino-3-[18F]fluoromethyl-5-methyl-adamantane (18F-MEM): A Potential Radioligand for Mapping the NMDA-Receptor Complex. <i>Nuclear Medicine and Biology</i> , 1998, 25, 323-330.	0.3	41
60	Budipine is a low affinity, N-methyl-d-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones. <i>Neuropharmacology</i> , 1998, 37, 719-727.	2.0	21
61	Interactions of GYKI 52466 and NBQX with cyclothiazide at AMPA receptors: experiments with outside-out patches and EPSCs in hippocampal neurones. <i>Neuropharmacology</i> , 1998, 37, 1299-1320.	2.0	32
62	Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. <i>British Journal of Pharmacology</i> , 1996, 117, 689-697.	2.7	119
63	Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. <i>British Journal of Pharmacology</i> , 1996, 119, 195-204.	2.7	90
64	Interactions of 2,3-benzodiazepines and cydothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. <i>British Journal of Pharmacology</i> , 1996, 117, 1209-1221.	2.7	47
65	Zinc changes AMPA receptor properties: Results of binding studies and patch clamp recordings. <i>Neuropharmacology</i> , 1996, 35, 503-509.	2.0	42
66	Learning deficits induced by chronic intraventricular infusion of quinolinic acid are protected by MK-801 and memantine. <i>European Journal of Pharmacology</i> , 1996, 296, 1-8.	1.7	88
67	Effects of the Uncompetitive NMDA Receptor Antagonist Memantine on Hippocampal Long-term Potentiation, Short-term Exploratory Modulation and Spatial Memory in Awake, Freely Moving Rats. <i>European Journal of Neuroscience</i> , 1996, 8, 565-571.	1.2	134
68	Memantine selectively depresses NMDA receptor-mediated responses of rat spinal neurones in vivo. <i>Neuroscience Letters</i> , 1994, 165, 37-40.	1.0	28
69	Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). <i>Neuropharmacology</i> , 1993, 32, 1337-1350.	2.0	271
70	Whole cell and single channel analysis of the kinetics of glycine-sensitive N-methyl-D-aspartate receptor desensitization. <i>British Journal of Pharmacology</i> , 1993, 109, 213-221.	2.7	37
71	Effects of intravenous $\mu$ and $\delta$ opioid receptor agonists on sensory responses of convergent neurones in the dorsal horn of spinalized rats. <i>British Journal of Pharmacology</i> , 1991, 103, 1230-1236.	2.7	14
72	Peripheral opioid receptors mediating antinociception in inflammation. Activation by endogenous opioids and role of the pituitary-adrenal axis. <i>Pain</i> , 1990, 41, 81-93.	2.0	61

#	ARTICLE	IF	CITATIONS
73	Spinal antinociceptive actions of $\mu$ - and $\delta$ -opioids: the importance of stimulus intensity in determining $\mu$ -selectivity <sup>TM</sup> between reflexes to different modalities of noxious stimulus. British Journal of Pharmacology, 1989, 98, 523-532.	2.7	42
74	Spinal antinociceptive actions and naloxone reversibility of intravenous $\mu$ - and $\delta$ -opioids in spinalized rats: potency mismatch with values reported for spinal administration. British Journal of Pharmacology, 1989, 98, 533-543.	2.7	27
75	On the selectivity of intravenous $\mu$ - and $\delta$ -opioids between nociceptive and non-nociceptive reflexes in the spinalized rat. British Journal of Pharmacology, 1989, 98, 544-551.	2.7	9